Tuesday January 16th 2018

Early netrin‐1 expression impairs central nervous system remyelination

Abstract Objective: Chronically demyelinated multiple sclerosis (MS) lesions are frequently characterized by scarce undifferentiated oligodendrocyte progenitor cells (OPCs) suggesting the exhaustion of a local OPC pool followed by failure of recruitment and differentiation. Stimulating prompt OPC recruitment following demyelination could improve myelin repair by providing sufficient numbers of remyelinating cells during the “repair‐permissive” period. Understanding mechanisms that determine this process may have important therapeutic implications. We therefore investigated the role of the guidance molecule netrin‐1 in OPC recruitment and CNS remyelination. Methods: Netrin‐1 expression was analysed immunohistochemically in different types of MS lesions and in the murine lysolecith…

Visit site:  

Early netrin‐1 expression impairs central nervous system remyelination

Leave a Comment

More from category

FDA Denies Health Claim for Vitamin D to Prevent MS FDA Denies Health Claim for Vitamin D to Prevent MS
FDA Denies Health Claim for Vitamin D to Prevent MS FDA Denies Health Claim for Vitamin D to Prevent MS

The FDA responded to a petition, saying that after reviewing the evidence, there is no basis for the claim that vitamin [Read More]

Effects of sport climbing on multiple sclerosis – Steimer J, Weissert R.
Effects of sport climbing on multiple sclerosis – Steimer J, Weissert R.

Multiple sclerosis (MS) is an autoimmune and neurodegenerative disease of the central nervous system (CNS) with [Read More]

Researchers use novel PET tracer to assess myelin damage in mouse models of MS
Researchers use novel PET tracer to assess myelin damage in mouse models of MS

The loss or damage of myelin, a cellular sheath that surrounds and insulates nerves, is the hallmark of the [Read More]

MS Drug Ocrelizumab (Ocrevus) Approved in Europe MS Drug Ocrelizumab (Ocrevus) Approved in Europe
MS Drug Ocrelizumab (Ocrevus) Approved in Europe MS Drug Ocrelizumab (Ocrevus) Approved in Europe

The European Commission clears the anti-CD20 monoclonal antibody for adults with relapsing multiple sclerosis and early [Read More]

New PET radiotracer offers insight into multiple sclerosis
New PET radiotracer offers insight into multiple sclerosis

Combining PET scans with a novel radiotracer could help researchers track damage...Read more on AuntMinnie.comRelated [Read More]